Eikon Therapeutics

Company snapshot

Eikon Therapeutics is a late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs. We are passionate about novel therapeutics and share the belief that a better understanding of fundamental human disease biology can lead to better medicines. We are driven to go beyond incremental improvements. Instead, our goal is to introduce n

• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 15 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Eikon Therapeutics. Not investment advice.

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 50

• Peer + 0 momentum

  Daiichi Sankyo US

  TA overlap score 31.6

• Peer + 0 momentum

  Farmatek

  TA overlap score 25.2

• Peer + 0 momentum

  Kura Oncology

  TA overlap score 25

• Peer + 0 momentum

  Centessa Pharmaceuticals

  TA overlap score 23

• Peer + 0 momentum

  Pyxis Oncology

  TA overlap score 21.6

• Peer + 0 momentum

  Turn Therapeutics

  TA overlap score 21.2

• Peer + 0 momentum

  Sichuan Kelun Pharmaceutical

  TA overlap score 20.8

• Peer + 0 momentum

  Medicenna Therapeutics

  TA overlap score 20.6

• Peer + 0 momentum

  Immix Biopharma

  TA overlap score 20.6

Recent activity

Latest pipeline, patent, and corporate events for Eikon Therapeutics.

1. Jun 8, 2026 Clinical update

   EIK1005-002 — Phase 2

2. Jun 8, 2026 Clinical update

   EIK1003-001 — Phase 2

3. Jun 8, 2026 Clinical update

   EIK1001-008 — Phase 2

4. Jun 8, 2026 Clinical update

   EIK1001-006 — Phase 3

5. Jun 5, 2026 Clinical update

   EIK1004 20mg Tablets, EIK1004 5mg Tablets — Phase 2

View all clinical trial activity →

• What is Eikon Therapeutics?

  Eikon Therapeutics is a biotech organization headquartered in Millbrae, USA. It trades on NYSE under ticker EIKN. Primary therapeutic focus areas include Advanced Solid Tumors, Tumor, Solid, Advanced Melanoma, Advanced solid tumors, Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

• Is Eikon Therapeutics publicly traded?

  Yes. Eikon Therapeutics is listed with ticker EIKN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Eikon Therapeutics develop or market?

  We link 13 drug profile(s) where Eikon Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/eikon-therapeutics#company-drugs.

• What are the latest developments for Eikon Therapeutics?

  In the last 12 months our linked public records show 15 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Eikon Therapeutics focus on?

  Eikon Therapeutics focuses on Advanced Solid Tumors, Tumor, Solid, Advanced Melanoma based on our analysis of their pipeline programs and drug development activities.